Cabell Christopher 4/A
4/A · Inhibikase Therapeutics, Inc. · Filed Jul 2, 2025
Insider Transaction Report
Form 4/AAmended
Cabell Christopher
President & Head of R&D
Transactions
- Award
Stock Option (Right to Buy)
2025-02-21+1,100,705→ 1,100,705 totalExercise: $2.97Exp: 2035-02-21→ Common Stock (1,100,705 underlying)
Footnotes (2)
- [F1]The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.
- [F2]The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.